Skip to main content
  • Vaccine development begins with basic laboratory research

  • 10th African Rotavirus Symposium in Bamako, Mali

  • Clinical trial for the NIH-developed Zika vaccine

  • Drs. Matt Laurens and Kathy Neuzil participated in the Fondation Mérieux event "Estimating the full public health value of vaccines"

Center for Vaccine Development (CVD)

CVD Overview

Life-saving immunizations are one of seven great achievements in pediatric research in the past 40 years (Cheng, Monteiro et al. 2016).

Since its inception in 1974, the CVD has worked to eliminate vaccine-preventable diseases. The CVD has created and tested vaccines against cholera, typhoid fever, paratyphoid fever, non-typhoidal salmonella disease, shigellosis (bacillary dysentery), Escherichia coli diarrhea, nosocomial pathogens, tularemia, influenza, and other infectious diseases. The faculty and global staff includes molecular biologists, microbiologists, immunologists, internists, pediatricians, epidemiologists, malariologists, and biostatisticians.

Vaccines are a powerful tool to fight infectious diseases worldwide. For over 40 years, the CVD at the University of Maryland School of Medicine (UM SOM) in Baltimore, MD has worked domestically and internationally to develop, test, and deploy vaccines to aid the world’s underserved populations. The CVD is an academic enterprise engaged in the full range of vaccinology from basic laboratory research through vaccine development, pre-clinical and clinical evaluation, large-scale pre-licensure field studies, and post-licensure assessments.

While the main research thrust of basic research at the CVD has historically focused on bacterial enteric pathogens, rotavirus, and malaria, it has also worked more broadly on bacterial diseases, parasitic diseases, viral diseases, novel delivery systems, public health, and vaccine policy.

Learn more about us in the CVD Fact Sheet.

History


Leadership

Dr. Neuzil brings over two decades of experience in infectious diseases and vaccine science, policy, and introduction. She’s led or been involved in pivotal vaccine trials that have influenced vaccine policy worldwide. A strong advocate for translating research results into vaccine policies, she was a key driver in the many changes in the influenza policy in the United States. Internationally, her research helped shape rotavirus vaccine policy. She is an expert on influenza, rotavirus, and RSV as well as in maternal immunization, optimizing vaccine use, and overcoming barriers to sustainable vaccine uptake in low resource settings.


Mission

Harness the power of vaccines to prevent disease and save lives in the most vulnerable populations.

Studies to support meeting our mission

Give to this Department

Connect with Us:

Kathleen Neuzil, MD, MPH
CVD Director & Deputy Director of the IGH


CVD NEWS

CVD-Mali Director, Samba Sow, MD, MS, speaks in CHAMPS 2016 about how consistent and reliable data can help to save young lives in Mali.

Kathleen Neuzil, MD, MPH was a co-author on Rotavirus Vaccine Effectiveness in Low-income Settings: An Evaluation of the Test-negative Design in the 3 Jan 2017 issue of Vaccine.

Myron M. Levine, MD, DTPH was a co-author on Efficacy and Effectiveness of an rVSV-vectored Vaccine in Preventing Ebola Virus Disease: Final Results from the Guinea Ring Vaccination, Open-label, Cluster-randomised Trial (Ebola Ça Suffit!) in the 23 Dec 2016 issue of The Lancet.

Wilbur H. Chen, MD, MS and Marcela F. Pasetti, PhD were two authors on Safety and Immunogenicity of a Parenterally Administered, Structure-Based Rationally Modified Recombinant Staphylococcal Enterotoxin B Protein Vaccine, STEBVax in the Dec 2016 issue of Clinical and Vaccine Immunology.

Karen Kotloff, MD and Myron M. Levine, MD, DTPH were two authors on Predictors of Diarrheal Mortality and Patterns of Caregiver Health Seeking Behavior in Karachi, Pakistan in the Dec 2016 issue of Journal of Global Health.

Archived News